Subscribe to RSS
DOI: 10.1055/s-0029-1245022
© Georg Thieme Verlag KG Stuttgart ˙ New York
Chronische Nierenerkrankung - Möglichkeiten der kardiorenalen Protektion
Publication History
Publication Date:
05 January 2010 (online)
Die Mehrzahl der Dialysepatienten verstirbt aufgrund kardiovaskulärer Ursachen [1]. Wie Prof. Eberhard Ritz, Heidelberg, auf dem Kongress für Nephrologie 2009 in Göttingen ausführte, erhöht eine geringe GFR-Reduktion (GFR: glomeruläre Filtrationsrate) - auch innerhalb des GFR-Normbereichs - bereits bei gesunden Menschen das relative Risiko für einen kardiovaskulären Tod sowie die Inzidenz koronarer Schädigungen [2], [3]. Das relative Risiko steigt um jeweils 1,26 pro 5 ml/min GFR-Verlust [4]. Hinter einer normalen GFR kann sich also eine deutliche Nierenfunktionsstörung verbergen, da die verbliebenen Nephrone mittels kompensatorischer Hyperfiltration eine lange Zeit die Funktionseinschränkung des Organs ausgleichen können.
Literatur
- 01 Wanner C . Krane V . März W . et al . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New Engl J Med. 2005; 353 238-248
- 02 Pereg D . Tirosh A . Shochat T . et al . Mild renal dysfunction associated with incident coronary artery disease in young males. Eur Heart J. 2008; 29 198-203
- 03 Van Biesen W . De Bacquer D . Verbeke F . et al . The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J. 2007; 28 478-483
- 04 Henry RM . Kostense PJ . Bos G . et al . Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002; 62 1402-1407
- 05 Stefanski A . Schmidt KG . Waldherr R . et al . Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int. 1996; 50 1321-1326
- 06 Shlipak MG . Fried LF . Crump C . et al . Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107 87-92
- 07 Landray MJ . Wheeler DC . Lip GY . et al . Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kid Dis. 2004; 43 244-253
- 08 Amann K . Wanner C . Ritz E . Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol. 2006; 17 2112-2119
- 09 Di Marco GS . Reuter S . Hillebrand U . et al . The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol. 2009; 20 2235-2245
- 10 David S . Kümpers P . Hellpap J . et al . Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation. Am J Kid Dis. 2009; 53 770-778
- 11 Isbel NM . Haluska B . Johnson DW . et al . Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J. 2006; 151 745-753
- 12 Teng M . Wolf M . Ofshun MN . et al . Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005; 16 1115-1125
- 13 Shoben AB . Rudser KD . De Boer IH . et al . Association of oral calcitriol with improved survival in nondialyzed CKD. Jam Soc Nephrol. 2008; 19 1613-1619
- 14 Teng M . Wolf M . Lowrie E . et al . Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349 446-456
- 15 Agarwal R . Acharya M . Tian J . et al . Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005; 68 2823-2828
- 16 Alborzi P . Patel NA . Peterson C . et al . Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008; 52 249-255
- 17 Fishbane S . Chittineni H . Packman M . et al . Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kid Dis. 2009; 54 647-652
- 18 Bodyak N . Ayus JC . Achinger S . et al . Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA. 2007; 104 16810-16815
- 19 Tan X . Li Y . Liu Y . Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol. 2006; 17 3382-3393
- 20 Mizobuchi M . Morrissey J . Finch JL . et al . Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. JASN. 2007; 18 1796-1806
- 21 Mizobuchi M . Finch JL . Martin DR . et al . Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kid Int. 2007; 72 709-715
- 22 Coyne D . Acharya M . Qiu P . et al . Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kid Dis. 2006; 47 263-276
- 23 Hamdy NA . Kanis JA . Beneton MN . et al . Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ. 1995; 310 358-363
- 24 Sprague SM . Llach F . Amdahl M . et al . Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 63 1483-1490
- 25 Ross EA . Kant KS . Melnick JZ . et al . Comparison of Two Dosing Regimens of Oral Paricalcitol for Secondary Hyperparathryoidism (SHPT) in Peritoneal Dialysis (PD) Patients. [ASN Poster TH-PO722]. JASN. 2006; 17 691
- 26 Nordal KP . Dahl E . Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrin Metab. 1988; 67 929-936
- 27 US Food and Drug Administration .Rocaltrol/Calcitriol oral solution and capsules. Im Internet: www.fda.gov .
- 28 Slatopolsky E . Cozzolino M . Finch JL . Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int. 2002; 62 1277-1284